DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: OPTISON

Summary for Tradename: OPTISON

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 OPTISON

Pharmacology for Tradename: OPTISON

Clinical Trials for: OPTISON

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
Status: Completed Condition: Echocardiography

Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Status: Completed Condition: Abdominal Neoplasms; Pelvic Neoplasms

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
Status: Terminated Condition: Carotid Artery Disease

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Status: Completed Condition: Pulmonary Hypertension

Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage
Status: Not yet recruiting Condition: Atrial Fibrillation

Contrast-Enhanced Ultrasound in Human Crohn's Disease
Status: Not yet recruiting Condition: Crohn's Disease

Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma
Status: Not yet recruiting Condition: Abdominal Trauma

Pre-operative Evaluation of Kidney & Pancreas Transplant Patients
Status: Active, not recruiting Condition: Kidney Transplantation; Pancreas Transplantation

Detection of Coronary Stenosis With Intravenous Microbubbles
Status: Withdrawn Condition: Coronary Stenosis; Carotid Stenosis; Myocardial Reperfusion

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899Dec 31, 1997RXYes<disabled><disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899Dec 31, 1997RXYes6,723,303<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc